Nicholas Conger, MD
Infectious Disease · Wright Patterson Afb, OHNPI 1598743890
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,225 of the $75,978 with a category attached, or 74.0%. Viiv Healthcare Company accounts for 88.5% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $45,282, more than ten times the $1,131 reported in 2019. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 659 payments — averaging $115.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$67K
- Gilead$2K
- Astellas Pharma US Inc$1K
- Insmed, Inc.$1K
- Merck$1K
- Melinta Therapeutics, LLC$812
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$56,22574%
- Travel & lodging$6,4028%
- Food & beverage$13,08517%
- Education$2650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 194 | $67,227 |
| Gilead | 91 | $1,759 |
| Astellas Pharma US Inc | 47 | $1,138 |
| Insmed, Inc. | 63 | $1,073 |
| Merck | 56 | $1,062 |
| Melinta Therapeutics, LLC | 51 | $812 |
| Paratek Pharmaceuticals, Inc. | 44 | $621 |
| AbbVie(2 entities) | 22 | $396 |
| Shionogi Inc | 14 | $304 |
| Accelerate Diagnostics Inc. | 9 | $263 |
| Dynavax Technologies Corporation | 1 | $183 |
| Theratechnologies Inc. | 8 | $171 |
| Johnson & Johnson | 7 | $119 |
| La Jolla Pharmaceutical Company | 7 | $115 |
| Cumberland Pharmaceuticals, Inc. | 7 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
| Invivyd Inc | 2 | $39 |
| EMD Serono, Inc. | 3 | $36 |
| Pharmacosmos Therapeutics Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $27 |
| Pfizer | 2 | $25 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| Qiagen, LLC | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| UCB, Inc. | 1 | $18 |
| Organogenesis Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Biomerieux Inc | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Advanced Oxygen Therapy Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CABENUVA$61,972
- Heplisav-B$183
How this compares
$75,978 in reported general payments places this provider in the 95th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 11 | $169,038 |
| Daptomycin | 84 | $158,958 |
| CabenuvaCabotegravir/Rilpivirine | 22 | $111,490 |
| DovatoDolutegravir Sodium/Lamivudine | 30 | $85,883 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $51,378 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $31,910 |
| PifeltroDoravirine | 18 | $31,674 |
| TivicayDolutegravir Sodium | 13 | $29,455 |
| IsentressRaltegravir Potassium | 12 | $23,303 |
| ErtapenemErtapenem Sodium | 46 | $22,243 |
| Cefepime Hcl | 59 | $15,820 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 51 | $9,429 |
| CeftriaxoneCeftriaxone Sodium | 73 | $7,917 |
| Vancomycin Hcl | 45 | $6,341 |
| Methenamine Hippurate | 104 | $6,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyCabenuva, Dovato, Tivicay | $67,227 | $226,82865 claims |
| Insmed, Inc.Arikayce | $1,073 | $169,03811 claims |
| GileadBiktarvy, Descovy | $1,759 | $83,28828 claims |
| MerckPifeltro, Isentress | $1,062 | $54,97730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 infectious disease providers in Ohio.
Other infectious disease in Wright Patterson Afb
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
- Thomas FileAkron$68K
- Nelson NicolasoraToledo$65K
- Benigno RodriguezCleveland$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.